Evidence map›Paper›PMID 33986264›Full record

ArticleNature communications2021

Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis.

Hongjun Li, Zejun Wang, Zhaowei Chen, Tianyuan Ci, Guojun Chen, Di Wen, Ruoxin Li, Jinqiang Wang, Huan Meng, R Bryan Bell and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Platelets as regulators of cancer immunity: mechanisms and therapeutic perspectives.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Article
  5. Review
  6. Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Cell-drug conjugates.Nature biomedical engineering · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Hongjun LiCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Zejun WangDepartment of Bioengineering, University of California, Los Angeles, CA, USA.ORCID 0000-0003-0313-5819
Zhaowei ChenCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Tianyuan CiDepartment of Bioengineering, University of California, Los Angeles, CA, USA.
Guojun ChenDepartment of Bioengineering, University of California, Los Angeles, CA, USA.
Di WenDepartment of Bioengineering, University of California, Los Angeles, CA, USA.
Ruoxin LiDepartment of Bioengineering, University of California, Los Angeles, CA, USA.
Jinqiang WangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Huan MengCalifornia NanoSystems Institute, University of California, Los Angeles, CA, USA.ORCID 0000-0001-8844-3938
R Bryan BellEarle A. Chiles Research Institute in the Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA.ORCID 0000-0002-3775-109X
Zhifeng GuResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China.ORCID 0000-0002-3275-0733
Gianpietro DottiJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, USA.ORCID 0000-0002-2639-8526
Zhen GuCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China. guzhen@zju.edu.cn.ORCID 0000-0003-2947-4456
California NanoSystems Institute · USUniversity of California, Los Angeles · USProvidence Portland Medical Center · USUniversity of North Carolina at Chapel Hill · US

Funding

Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer ImmunotherapyR01CA234343 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, SONG · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA234343
6 · The paper itself

Abstract

Although therapies of cancer are advancing, it remains challenging for therapeutics to reach the sites of metastasis, which accounts for majority of cancer associated death. In this study, we have developed a strategy that guides an anti-programmed cell death-ligand 1 (aPDL1) antibody to accumulate in metastatic lesions to promote anti-tumour immune responses. Briefly, we have developed a combination in which Vadimezan disrupts tumour blood vessels of tumour metastases and facilitates the recruitment and activation of adoptively transferred aPDL1-conjugated platelets. In situ activated platelets generate aPDL1-decorated platelet-derived microparticles (PMP) that diffuse within the tumour and elicit immune responses. The proposed combination increases 10-fold aPDL1 antibody accumulation in lung metastases as compared to the intravenous administration of the antibody and enhances the magnitude of immune responses leading to improved antitumour effects.

Indexed as

AnimalsAntineoplastic AgentsB7-H1 AntigenBlood PlateletsCell Line, TumorFemaleLung NeoplasmsMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasm MetastasisNeoplasmsPlatelet ActivationPlatelet TransfusionXanthonesAntineoplastic AgentsB7-H1 AntigenCd274 protein, mousevadimezanXanthones

Identifiers

PMID33986264
PMCPMC8119987
OpenAlexW3160539044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.